Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from William Blair

Share on StockTwits

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reiterated by investment analysts at William Blair in a report issued on Friday, TipRanks reports.

A number of other research firms also recently commented on ACRS. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Wednesday, September 25th. ValuEngine raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Leerink Swann downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. Svb Leerink downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. Finally, JMP Securities downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, September 6th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Aclaris Therapeutics currently has an average rating of “Hold” and a consensus target price of $13.38.

ACRS traded down $0.01 on Friday, reaching $1.41. 1,267,791 shares of the company traded hands, compared to its average volume of 3,272,535. Aclaris Therapeutics has a one year low of $0.74 and a one year high of $13.73. The firm has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $3.38. The company has a market cap of $49.23 million, a P/E ratio of -0.35 and a beta of 0.83. The company has a quick ratio of 3.22, a current ratio of 3.23 and a debt-to-equity ratio of 0.22.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.05. Aclaris Therapeutics had a negative net margin of 979.65% and a negative return on equity of 81.40%. The company had revenue of $5.87 million during the quarter, compared to analyst estimates of $5.77 million. On average, equities analysts forecast that Aclaris Therapeutics will post -2.58 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Man Group plc increased its position in Aclaris Therapeutics by 73.6% during the 2nd quarter. Man Group plc now owns 2,057,936 shares of the biotechnology company’s stock valued at $4,507,000 after purchasing an additional 872,408 shares during the period. Rock Springs Capital Management LP increased its position in Aclaris Therapeutics by 19.3% during the 2nd quarter. Rock Springs Capital Management LP now owns 2,028,000 shares of the biotechnology company’s stock valued at $4,441,000 after purchasing an additional 328,000 shares during the period. Vanguard Group Inc. increased its position in Aclaris Therapeutics by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,867,838 shares of the biotechnology company’s stock valued at $4,090,000 after purchasing an additional 30,191 shares during the period. Renaissance Technologies LLC increased its position in Aclaris Therapeutics by 63.7% during the 2nd quarter. Renaissance Technologies LLC now owns 699,580 shares of the biotechnology company’s stock valued at $1,532,000 after purchasing an additional 272,200 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Aclaris Therapeutics by 66.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 408,262 shares of the biotechnology company’s stock worth $870,000 after buying an additional 162,458 shares during the last quarter. 86.10% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Further Reading: Market Capitalization and Individual Investors

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Janney Montgomery Scott LLC Sells 16,501 Shares of Braemar Hotels & Resorts
Janney Montgomery Scott LLC Sells 16,501 Shares of Braemar Hotels & Resorts
Rhumbline Advisers Grows Stake in Westlake Chemical Co.
Rhumbline Advisers Grows Stake in Westlake Chemical Co.
Rhumbline Advisers Purchases 578 Shares of Shenandoah Telecommunications
Rhumbline Advisers Purchases 578 Shares of Shenandoah Telecommunications
Rhumbline Advisers Acquires 5,900 Shares of William Lyon Homes
Rhumbline Advisers Acquires 5,900 Shares of William Lyon Homes
Rhumbline Advisers Has $2.18 Million Holdings in Extended Stay America
Rhumbline Advisers Has $2.18 Million Holdings in Extended Stay America
Bezant  Price Tops $0.0041 on Top Exchanges
Bezant Price Tops $0.0041 on Top Exchanges


 
© 2006-2019 Zolmax.